Option Care Health (OPCH)
Market Price (6/27/2026): $21.76 | Market Cap: $3.4 BilSector: Health Care | Industry: Health Care Facilities
Option Care Health (OPCH)
Market Price (6/27/2026): $21.76Market Cap: $3.4 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.0%, FCF Yield is 6.2% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -32% Low stock price volatilityVol 12M is 41% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Oncology Treatments, Show more. | Weak multi-year price returns2Y Excs Rtn is -57%, 3Y Excs Rtn is -95% | Key risksOPCH key risks include [1] persistent margin pressure from reduced reimbursement rates by third-party payers and [2] an anticipated negative impact on 2025 gross profit due to a key supplier's pricing change on a specific therapy. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.0%, FCF Yield is 6.2% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -32% |
| Low stock price volatilityVol 12M is 41% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Oncology Treatments, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -57%, 3Y Excs Rtn is -95% |
| Key risksOPCH key risks include [1] persistent margin pressure from reduced reimbursement rates by third-party payers and [2] an anticipated negative impact on 2025 gross profit due to a key supplier's pricing change on a specific therapy. |
Qualitative Assessment
AI Analysis | Feedback
Option Care Health (OPCH) stock has lost about 35% since 2/28/2026 because of the following key factors:
1. Disappointing Q1 2026 Revenue and Reduced Full-Year Guidance. Option Care Health reported Q1 2026 net revenue of $1.35 billion, falling short of analysts' consensus estimate of approximately $1.40 billion. This revenue miss, coupled with a significant reduction in full-year 2026 revenue guidance from a range of $5.8 billion to $6.0 billion (reaffirmed on February 24, 2026) to a new range of $5.675 billion to $5.775 billion, caused the stock to plummet by approximately 26.4% to 29.1% on April 30, 2026. The revised guidance represented a reduction of up to 3.75%, or $225 million, from the top end of the prior range and indicated a projected year-over-year growth of only about 1% at the midpoint, down from the previously expected 4%.
2. Weakness in Chronic Inflammatory Disease (CID) Portfolio. A core reason for the lowered revenue guidance was "lower CID patient retention and therapy mix." Management anticipates these chronic inflammatory disease dynamics will reduce the company's 2026 gross profit by approximately $55 million. This factor also contributed to a negative 600 basis point revenue growth headwind, which was an increase from the previously disclosed 400 basis point headwind related to Stelara biosimilar competition.
Show more
Option Care Health (OPCH) stock has lost about 35% since 2/28/2026 because of the following key factors:
1. Disappointing Q1 2026 Revenue and Reduced Full-Year Guidance. Option Care Health reported Q1 2026 net revenue of $1.35 billion, falling short of analysts' consensus estimate of approximately $1.40 billion. This revenue miss, coupled with a significant reduction in full-year 2026 revenue guidance from a range of $5.8 billion to $6.0 billion (reaffirmed on February 24, 2026) to a new range of $5.675 billion to $5.775 billion, caused the stock to plummet by approximately 26.4% to 29.1% on April 30, 2026. The revised guidance represented a reduction of up to 3.75%, or $225 million, from the top end of the prior range and indicated a projected year-over-year growth of only about 1% at the midpoint, down from the previously expected 4%.
2. Weakness in Chronic Inflammatory Disease (CID) Portfolio. A core reason for the lowered revenue guidance was "lower CID patient retention and therapy mix." Management anticipates these chronic inflammatory disease dynamics will reduce the company's 2026 gross profit by approximately $55 million. This factor also contributed to a negative 600 basis point revenue growth headwind, which was an increase from the previously disclosed 400 basis point headwind related to Stelara biosimilar competition.
3. Negative Operating Cash Flow in Q1 2026. The company reported a negative operating cash flow, with $12.1 million cash used in operating activities and free cash flow of -$21.16 million in Q1 2026. This was a decline compared to -$16.59 million in the same quarter of the prior year, amplifying concerns about near-term fundamentals. Furthermore, Option Care Health reduced its full-year projection for cash provided by operating activities from a floor of $340 million to $320 million.
4. Significant Analyst Downgrades and Price Target Cuts. Following the Q1 results and revised guidance, several investment firms downgraded Option Care Health's stock and substantially reduced their price targets. For instance, Bank of America downgraded OPCH to Neutral from Buy and nearly halved its price target from $40 to $22. Zacks Research also downgraded the stock from "hold" to "strong sell." Other notable price target reductions included Barrington Research (from $42 to $32), TD Cowen (from $37 to $23), Morgan Stanley (from $38 to $28), and J.P. Morgan (from $40 to $33).
5. Shareholder Investigations into Prior Guidance. The rapid and significant downward revision of the company's full-year 2026 revenue guidance, just 65 days after it was reaffirmed, led to multiple law firms, including Levi & Korsinsky and Kirby McInerney LLP, initiating investigations into Option Care Health for potential federal securities law violations and securities fraud.
Show less
Stock Movement Drivers
Fundamental Drivers
The -32.8% change in OPCH stock from 2/28/2026 to 6/26/2026 was primarily driven by a -33.0% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 6262026 | Change |
|---|---|---|---|
| Stock Price ($) | 32.46 | 21.82 | -32.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,650 | 5,667 | 0.3% |
| Net Income Margin (%) | 3.7% | 3.6% | -1.0% |
| P/E Multiple | 24.7 | 16.6 | -33.0% |
| Shares Outstanding (Mil) | 158 | 157 | 1.0% |
| Cumulative Contribution | -32.8% |
Market Drivers
2/28/2026 to 6/26/2026| Return | Correlation | |
|---|---|---|
| OPCH | -32.8% | |
| Market (SPY) | 6.6% | -3.6% |
| Sector (XLV) | 0.5% | -7.3% |
Fundamental Drivers
The -29.8% change in OPCH stock from 11/30/2025 to 6/26/2026 was primarily driven by a -31.1% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 6262026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.10 | 21.82 | -29.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,530 | 5,667 | 2.5% |
| Net Income Margin (%) | 3.8% | 3.6% | -3.8% |
| P/E Multiple | 24.1 | 16.6 | -31.1% |
| Shares Outstanding (Mil) | 162 | 157 | 3.3% |
| Cumulative Contribution | -29.8% |
Market Drivers
11/30/2025 to 6/26/2026| Return | Correlation | |
|---|---|---|
| OPCH | -29.8% | |
| Market (SPY) | 7.3% | -3.9% |
| Sector (XLV) | 2.6% | 2.6% |
Fundamental Drivers
The -33.2% change in OPCH stock from 5/31/2025 to 6/26/2026 was primarily driven by a -34.5% change in the company's P/E Multiple.| (LTM values as of) | 5312025 | 6262026 | Change |
|---|---|---|---|
| Stock Price ($) | 32.68 | 21.82 | -33.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,185 | 5,667 | 9.3% |
| Net Income Margin (%) | 4.1% | 3.6% | -11.8% |
| P/E Multiple | 25.3 | 16.6 | -34.5% |
| Shares Outstanding (Mil) | 165 | 157 | 5.6% |
| Cumulative Contribution | -33.2% |
Market Drivers
5/31/2025 to 6/26/2026| Return | Correlation | |
|---|---|---|
| OPCH | -33.2% | |
| Market (SPY) | 25.1% | 7.4% |
| Sector (XLV) | 23.0% | 13.3% |
Fundamental Drivers
The -20.8% change in OPCH stock from 5/31/2023 to 6/26/2026 was primarily driven by a -47.1% change in the company's P/E Multiple.| (LTM values as of) | 5312023 | 6262026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.55 | 21.82 | -20.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,045 | 5,667 | 40.1% |
| Net Income Margin (%) | 3.9% | 3.6% | -7.7% |
| P/E Multiple | 31.3 | 16.6 | -47.1% |
| Shares Outstanding (Mil) | 181 | 157 | 15.7% |
| Cumulative Contribution | -20.8% |
Market Drivers
5/31/2023 to 6/26/2026| Return | Correlation | |
|---|---|---|
| OPCH | -20.8% | |
| Market (SPY) | 81.3% | 18.0% |
| Sector (XLV) | 31.9% | 26.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OPCH Return | 82% | 6% | 12% | -31% | 37% | -33% | 37% |
| Peers Return | 11% | -21% | 56% | 16% | 29% | 14% | 133% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| OPCH Win Rate | 58% | 50% | 67% | 42% | 50% | 50% | |
| Peers Win Rate | 46% | 38% | 44% | 52% | 58% | 62% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OPCH Max Drawdown | -22% | -66% | -25% | -37% | -26% | -47% | |
| Peers Max Drawdown | -22% | -38% | -29% | -26% | -37% | -26% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CVS, UNH, AVAH, ADUS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/26/2026 (YTD)
How Low Can It Go
| Event | OPCH | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -19.2% | -9.5% |
| % Gain to Breakeven | 23.7% | 10.5% |
| Time to Breakeven | 55 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -65.6% | -24.5% |
| % Gain to Breakeven | 190.3% | 32.4% |
| Time to Breakeven | 60 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -65.5% | -33.7% |
| % Gain to Breakeven | 189.6% | 50.9% |
| Time to Breakeven | 307 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -16.6% | -19.2% |
| % Gain to Breakeven | 19.9% | 23.8% |
| Time to Breakeven | 11 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -65.1% | -3.7% |
| % Gain to Breakeven | 186.3% | 3.9% |
| Time to Breakeven | 188 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -17.9% | -12.2% |
| % Gain to Breakeven | 21.9% | 13.9% |
| Time to Breakeven | 7 days | 62 days |
In The Past
Option Care Health's stock fell -5.1% during the 2025 US Tariff Shock. Such a loss loss requires a 5.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | OPCH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -65.6% | -24.5% |
| % Gain to Breakeven | 190.3% | 32.4% |
| Time to Breakeven | 60 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -65.5% | -33.7% |
| % Gain to Breakeven | 189.6% | 50.9% |
| Time to Breakeven | 307 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -65.1% | -3.7% |
| % Gain to Breakeven | 186.3% | 3.9% |
| Time to Breakeven | 188 days | 6 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -84.9% | -6.8% |
| % Gain to Breakeven | 560.9% | 7.3% |
| Time to Breakeven | 2388 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -25.9% | -17.9% |
| % Gain to Breakeven | 35.0% | 21.8% |
| Time to Breakeven | 210 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -54.8% | -15.4% |
| % Gain to Breakeven | 121.4% | 18.2% |
| Time to Breakeven | 796 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -84.0% | -53.4% |
| % Gain to Breakeven | 525.7% | 114.4% |
| Time to Breakeven | 355 days | 1085 days |
In The Past
Option Care Health's stock fell -5.1% during the 2025 US Tariff Shock. Such a loss loss requires a 5.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Option Care Health (OPCH)
Option Care Health (OPCH) is a prominent healthcare company specializing in the provision of home and alternate site infusion services throughout the United States. The company's core business involves delivering critical medical therapies directly to patients' residences or other non-hospital settings, allowing individuals with a diverse array of acute and chronic conditions to receive specialized care outside of traditional inpatient facilities.
OPCH's extensive service portfolio covers numerous therapeutic areas. This includes anti-infective therapies, home infusion services for heart failure, and nutritional support for conditions such as stroke, cancer, and gastrointestinal diseases. The company also provides immunoglobulin infusion therapies for immune deficiencies, treatments for chronic inflammatory disorders like Crohn's disease and rheumatoid arthritis, and management for neurological conditions such as amyotrophic lateral sclerosis and duchenne muscular dystrophy. Additionally, Option Care Health offers therapies for bleeding disorders, high-risk pregnancies, pain management, chemotherapy, and respiratory ailments, often integrated with professional nursing support.
AI Analysis | Feedback
1. It's like a 'Mayo Clinic for infusion therapies,' but the treatments and expert nurses come directly to your home instead of you going to a central facility.
2. Think of it as 'Carvana for specialized medical infusions,' where Option Care Health brings complex, hospital-level treatments and expert nursing care directly to your home, bypassing traditional clinics.
AI Analysis | Feedback
- Anti-infective Infusion Therapies: Provides home infusion services for treating various infections.
- Heart Failure Infusion Therapies: Offers home infusion services specifically designed to treat heart failures.
- Nutrition Support Services: Delivers home parenteral and enteral nutrition for acute and chronic conditions like stroke, cancer, and gastrointestinal diseases.
- Immunoglobulin Infusion Therapies: Administers treatments for patients suffering from immune deficiencies.
- Chronic Inflammatory Disorder Treatments: Supplies therapies for conditions such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.
- Neurological Disorder Therapies: Manages the progression of neurological disorders like amyotrophic lateral sclerosis and duchenne muscular dystrophy through infusion.
- Bleeding Disorder Therapies: Provides infusion therapies tailored for various bleeding disorders.
- High-Risk Pregnancy Therapies: Offers essential therapies to support women through high-risk pregnancies.
- Other Specialized Infusion Therapies: Includes treatments for pain management, chemotherapy, and respiratory medications for various conditions.
- Nursing Services: Provides professional nursing support alongside infusion therapies.
AI Analysis | Feedback
Option Care Health (OPCH) primarily sells its home and alternate site infusion services to **individuals** (patients) in the United States. Based on the therapies and conditions mentioned in the company description, its customer base can be categorized as follows:
-
Patients with Complex and Chronic Conditions: This category includes individuals requiring ongoing infusion therapies for long-term management of conditions such as heart failure, neurological disorders (e.g., amyotrophic lateral sclerosis, duchenne muscular dystrophy), bleeding disorders, chronic inflammatory disorders (e.g., Crohn's disease, rheumatoid arthritis), and those needing home parenteral or enteral nutrition support for various acute and chronic conditions.
-
Patients Requiring Anti-infective and Acute Care Therapies: This segment comprises individuals receiving anti-infective therapies, as well as those needing infusion services for pain management, chemotherapy for cancer treatment, and respiratory medications, often for more acute or specific treatment courses.
-
Patients with Immune Deficiencies and High-Risk Pregnancy Needs: This category serves specialized patient populations, specifically those requiring immunoglobulin infusion therapies for the treatment of immune deficiencies and women needing specialized therapies to manage high-risk pregnancies.
AI Analysis | Feedback
- McKesson Corporation (MCK)
- Cencora (COR)
- Cardinal Health, Inc. (CAH)
AI Analysis | Feedback
John C. Rademacher, President and Chief Executive Officer
John C. Rademacher was appointed CEO of Option Care Health in January 2018, having previously served as interim CEO since August 2017. From 2015 to 2018, he was the company's Chief Operating Officer. Prior to joining Option Care Health, Mr. Rademacher held various executive-level positions at leading healthcare companies. These roles included President of Ambulatory Care (2012-2014) and President of Nuclear & Pharmacy Services (2007-2012) at Cardinal Health, Inc., a publicly-traded multinational healthcare services company. He also served as President of CareAllies and Chief Operating Officer for the CIGNA Behavioral Health business at Cigna Corporation, where he was responsible for developing and delivering care management and population health programs.
Meenal Sethna, Chief Financial Officer
Meenal Sethna assumed the role of Chief Financial Officer for Option Care Health on October 1, 2025. Before joining Option Care Health, she served as CFO of Littelfuse, an industrial technology manufacturing company. Ms. Sethna has also held leadership positions at Illinois Tool Works, a specialized industrial equipment and consumables manufacturer, and has worked at Motorola and Baxter International.
Luke Whitworth, Chief Operating Officer
Luke Whitworth brings extensive healthcare and leadership experience to Option Care Health. He spent nearly fifteen years at Cardinal Health, where he gained a track record of accomplishment across Finance, Mergers and Acquisitions, Integration, Sales, and General Management. At Cardinal Health, he served as the finance executive responsible for building a multi-billion dollar post-acute business spanning distribution, services, and technology. He also held sales and general management responsibility for Home Healthcare Solutions, driving significant growth, customer acquisition, and efficiency.
Collin Smyser, General Counsel and Corporate Secretary
Collin Smyser serves as the General Counsel and Corporate Secretary for Option Care Health. Before joining the company, Mr. Smyser was the Vice President, Deputy General Counsel for Elanco Animal Health Incorporated. In that role, he served as Elanco's chief corporate governance, securities, and corporate transactions attorney.
Michael Bavaro, Chief Human Resources Officer and Chief Diversity Officer
Michael Bavaro serves Option Care Health as the Chief Human Resources Officer and Chief Diversity Officer, with over 20 years of human resource leadership experience. Prior to joining Option Care Health in 2016, Mr. Bavaro was a divisional Vice President at Blue Cross Blue Shield of IL, TX, NM, MT & OK. He was responsible for all talent acquisition and workforce strategies at Blue Cross Blue Shield and served as the company's interim Diversity and Inclusion Officer. Mr. Bavaro also held senior HR roles at Career Education Corporation and United Airlines.
AI Analysis | Feedback
The key risks to Option Care Health (OPCH) include:
- Biosimilar Competition and Margin Compression: The introduction of biosimilars for key high-margin drugs, such as Stelara, is significantly impacting Option Care Health's gross profit and overall margins. This loss of exclusivity for branded drugs and a shift in product mix toward lower-margin therapies, along with rising drug costs, is creating a substantial financial headwind for the company, with projected impacts of tens of millions of dollars on gross profit.
- Reimbursement Pressures and Dependence on Third-Party Payers: Option Care Health is highly dependent on third-party payers, including managed care organizations and government programs like Medicare and Medicaid, for a significant portion of its revenue. Changes in reimbursement policies and rates, including federal reimbursement pressures and potential price cuts, can directly reduce the company's revenue and profitability.
- Labor Shortages and Inability to Attract and Retain Skilled Clinicians: The healthcare sector is experiencing ongoing workforce shortages, particularly for skilled clinicians such as nurses, who are essential for Option Care Health's home and alternate site infusion services. An inability to attract and retain qualified staff could hinder the company's ability to provide services, support growth, and may lead to increased operational costs.
AI Analysis | Feedback
The primary emerging threat to Option Care Health stems from the ongoing advancements in pharmaceutical development, specifically the increasing prevalence and adoption of alternative, non-infusion drug delivery methods. Many conditions currently requiring intravenous (IV) infusion therapies, which form the core of Option Care Health's services, are seeing the emergence of equally effective and more convenient oral medications or self-administered subcutaneous injectable therapies. As these non-infusion alternatives gain market share, the demand for traditional infusion services could diminish for a significant portion of the conditions Option Care Health treats, directly impacting its business model and patient volumes.
AI Analysis | Feedback
For Option Care Health (symbol: OPCH), the addressable markets for its main products and services in the United States are as follows:
- Overall U.S. Home Infusion Therapy Market: The U.S. home infusion therapy market was valued at approximately USD 19.65 billion in 2024 and is projected to grow to about USD 38.02 billion by 2032. Other estimates for the U.S. market in 2024 range from USD 20.42 billion to USD 21.3 billion, with projections reaching USD 39.96 billion to USD 41.0 billion by 2033. Option Care Health itself estimates the home infusion market at USD 17 billion to USD 18 billion.
- Anti-infective Therapies (Home Infusion): This segment constituted a significant portion of the U.S. home infusion therapy market, holding a share of approximately 26.94% in 2024. Another source indicates it held a 27% share in 2025.
-
Immunoglobulin Infusion Therapies (IVIG and SCIG) in the U.S.:
- The U.S. Intravenous Immunoglobulin (IVIG) market was valued at USD 7.02 billion in 2024 and is projected to reach USD 14.03 billion by 2033. Another estimate places the U.S. IVIG market at USD 7.27 billion in 2024, projected to reach USD 14.42 billion by 2033. Within the U.S. home infusion therapy market, immunoglobulin therapy was the largest indication segment, accounting for 31.2% market share in 2024.
- The U.S. Subcutaneous Immunoglobulin (SCIG) market size was valued at USD 3.86 billion in 2024 and is expected to grow to USD 9.46 billion by 2034.
-
Home Parenteral and Enteral Nutrition Support Services (U.S.):
- The U.S. enteral nutrition products market was valued at USD 2.84 billion in 2023 and is projected to grow to USD 4.86 billion by 2032. Within the U.S. home infusion therapy market, the enteral nutrition segment was valued at USD 3.5 billion in 2024.
- The U.S. parenteral nutrition market generated a revenue of USD 2.57 billion in 2023 and is expected to reach USD 3.84 billion by 2030. The broader North American homecare clinical nutrition market (which includes both enteral and parenteral) was valued at USD 7.62 billion in 2025.
- Chemotherapy (Home Infusion) in the U.S.: The chemotherapy at home services market in the United States is expected to reach a projected revenue of approximately USD 1.06 billion by 2030. Chemotherapy infusion is identified as a rapidly growing application within the home infusion market.
- Pain Management (Infusion Therapies) in the U.S.: The U.S. pain management devices market, which includes analgesic infusion pumps, generated USD 2.97 billion in revenue in 2024 and is expected to reach USD 4.93 billion by 2030.
- Treatments for Neurological Disorders (Home Infusion) in the U.S.: The outpatient infusion market (including at home) for neurological conditions is expanding and is projected to reach nearly USD 38.0 billion by 2034.
AI Analysis | Feedback
- Expansion of Therapy Portfolio: Option Care Health is strategically broadening its therapy portfolio, with a significant focus on new treatments for acute and chronic care categories. This includes substantial investments in specialty areas such as oncology services, particularly PD-1 drugs, and neurology. The company aims to advance specialized therapies through collaborations.
- Geographic and Site of Care Expansion: The company is actively pursuing growth by expanding its physical infrastructure and increasing patient access. In the first quarter of 2025, Option Care Health opened three new infusion clinics. The company has also been expanding its infusion suites, adding over 80 infusion chairs and implementing more than 25 advanced practitioner-capable locations. This expansion also includes new pharmacies and infusion suites in various locations.
- Strategic Mergers and Acquisitions (M&A): Mergers and acquisitions are a crucial component of Option Care Health's expansion strategy. The company is actively exploring strategic M&A opportunities to bolster future growth, diversify its revenue streams, and increase market share in the healthcare services sector.
- Deepening Partnerships with Payers and Pharmaceutical Manufacturers: Option Care Health emphasizes deepening its partnerships with key stakeholders, including payers and pharmaceutical manufacturers. These collaborations are essential for accessing new customers, adapting to industry changes, securing favorable reimbursement rates, and supporting new drug launches and patient support programs. The company added five new regional health plan programs and two with non-traditional payers in 2025.
- Technology Investments and Operational Efficiency: The company is investing in technology, particularly in artificial intelligence (AI) and robotic process automation, to enhance patient onboarding and benefits verification. These efficiency initiatives have already shown positive impacts, with approximately 40% of claims being processed without human intervention.
AI Analysis | Feedback
Share Repurchases
- Option Care Health repurchased $307 million of shares in fiscal year 2025.
- From 2021 to the third quarter of 2025, the company repurchased a total of $715 million in shares.
- The board of directors expanded the share repurchase authorization by an additional $500 million, bringing the total authorization to $1.0 billion.
Share Issuance
- An affiliate of Walgreens Boots Alliance, Inc. sold 11,000,000 shares of Option Care Health common stock in August 2022.
- In March 2021, there was a secondary offering of 12,000,000 shares of common stock.
Outbound Investments
- Option Care Health acquired Intramed Plus in 2025.
- Strategic acquisitions ("M&A for strategic acquisitions" and "Strategic tuck-ins and near-adjacency acquisitions") are a stated capital allocation priority.
Capital Expenditures
- Option Care Health deployed $166 million for capital expenditures from 2021 to Q3 2025.
- The company's capital allocation priorities include organic investment in the business, such as opening new infusion suites and pharmacies, expanding its formulary, and investing in technology like AI for claims processing.
- Capital expenditures are described as modest.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 96.95 |
| Mkt Cap | 3.4 |
| Rev LTM | 5,667 |
| Op Inc LTM | 331 |
| FCF LTM | 213 |
| FCF 3Y Avg | 243 |
| CFO LTM | 254 |
| CFO 3Y Avg | 284 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.7% |
| Rev Chg 3Y Avg | 12.0% |
| Rev Chg Q | 6.2% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Inc Chg LTM | 8.3% |
| Op Inc Chg 3Y Avg | 9.7% |
| Op Mgn LTM | 5.8% |
| Op Mgn 3Y Avg | 6.9% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 5.1% |
| CFO/Rev 3Y Avg | 5.3% |
| FCF/Rev LTM | 4.4% |
| FCF/Rev 3Y Avg | 4.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.4 |
| P/S | 0.7 |
| P/Op Inc | 11.4 |
| P/EBIT | 12.2 |
| P/E | 17.7 |
| P/CFO | 13.4 |
| Total Yield | 5.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 5.2% |
| D/E | 0.4 |
| Net D/E | 0.3 |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Infusion Services | 5,556 | 4,912 | 4,223 | 3,945 | 3,439 |
| Other revenue | 94 | 87 | 80 | ||
| Total | 5,650 | 4,998 | 4,302 | 3,945 | 3,439 |
| $ Mil | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|
| Traditional Pharmacy Services | 17 | ||||
| Specialty Pharmacy Services | -1 | ||||
| PBM Services | 11 | 11 | 3 | -15 | |
| Specialty Services | -94 | -2 | -20 | -14 | |
| Total | 15 | -84 | 9 | -16 | -29 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Infusion Services | 208 | 212 |
| Total | 208 | 212 |
| $ Mil | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Infusion Services | 756 | 794 | 439 | ||
| Corporate unallocated | 40 | 53 | 105 | 23 | 76 |
| PBM Services | 29 | 25 | 36 | ||
| Home Health Services | 64 | 62 | |||
| Infusion/Home Health Services | 420 | 442 | |||
| Pharmacy Services | 234 | 146 | |||
| Total | 825 | 937 | 642 | 677 | 664 |
Price Behavior
| Market Price | $21.82 | |
| Market Cap ($ Bil) | 3.4 | |
| First Trading Date | 08/15/1996 | |
| Distance from 52W High | -40.4% | |
| 50 Days | 200 Days | |
| DMA Price | $22.34 | $28.39 |
| DMA Trend | down | down |
| Distance from DMA | -2.3% | -23.1% |
| 3M | 1YR | |
| Volatility | 62.8% | 41.1% |
| Downside Capture | -104.53 | 42.72 |
| Upside Capture | -130.15 | -13.15 |
| Correlation (SPY) | -10.9% | 7.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.71 | -0.34 | 0.23 | 0.07 | 0.41 | 0.49 |
| Up Beta | 3.05 | 0.76 | 0.59 | 0.19 | 0.37 | 0.26 |
| Down Beta | 0.91 | -0.25 | 1.29 | 1.15 | 0.63 | 0.45 |
| Up Capture | -102% | -116% | -87% | -57% | -2% | 22% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 10 | 19 | 24 | 52 | 108 | 371 |
| Down Capture | -440% | -86% | 75% | 12% | 77% | 93% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 10 | 22 | 38 | 71 | 139 | 374 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OPCH | |
|---|---|---|---|---|
| OPCH | -31.2% | 41.1% | -0.80 | - |
| Sector ETF (XLV) | 21.4% | 15.4% | 1.06 | 12.8% |
| Equity (SPY) | 21.2% | 12.4% | 1.26 | 7.0% |
| Gold (GLD) | 21.8% | 27.7% | 0.70 | -7.8% |
| Commodities (DBC) | 21.8% | 18.6% | 0.92 | -14.2% |
| Real Estate (VNQ) | 16.1% | 13.6% | 0.85 | 12.7% |
| Bitcoin (BTCUSD) | -44.7% | 42.5% | -1.27 | 1.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OPCH | |
|---|---|---|---|---|
| OPCH | 1.3% | 236.8% | 0.80 | - |
| Sector ETF (XLV) | 7.0% | 14.8% | 0.29 | 2.6% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 1.6% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | -2.9% |
| Commodities (DBC) | 7.4% | 19.5% | 0.28 | -3.3% |
| Real Estate (VNQ) | 3.4% | 18.9% | 0.08 | -0.9% |
| Bitcoin (BTCUSD) | 10.7% | 54.0% | 0.39 | 9.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OPCH | |
|---|---|---|---|---|
| OPCH | 10.2% | 174.2% | 0.66 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.51 | 8.0% |
| Equity (SPY) | 15.2% | 18.0% | 0.72 | 7.7% |
| Gold (GLD) | 11.8% | 16.1% | 0.60 | -2.3% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 0.4% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 5.5% |
| Bitcoin (BTCUSD) | 54.6% | 66.4% | 0.95 | 6.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/30/2026 | -24.3% | -23.9% | -22.3% |
| 2/24/2026 | -6.3% | -12.4% | -21.3% |
| 10/30/2025 | -8.6% | -5.5% | 7.9% |
| 7/30/2025 | 1.7% | -6.7% | -5.1% |
| 4/29/2025 | -6.9% | -0.5% | -3.7% |
| 2/26/2025 | 1.6% | 4.6% | 7.4% |
| 10/30/2024 | -22.8% | -26.8% | -22.1% |
| 7/31/2024 | -5.3% | -5.0% | 0.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 7 | 9 |
| # Negative | 11 | 14 | 12 |
| Median Positive | 5.4% | 8.4% | 7.4% |
| Median Negative | -8.6% | -9.6% | -10.6% |
| Max Positive | 147.9% | 157.3% | 169.6% |
| Max Negative | -24.3% | -26.8% | -22.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/30/2026 | -24.3% | -23.9% | -22.3% |
| 2/24/2026 | -6.3% | -12.4% | -21.3% |
| 10/30/2025 | -8.6% | -5.5% | 7.9% |
| 7/30/2025 | 1.7% | -6.7% | -5.1% |
| 4/29/2025 | -6.9% | -0.5% | -3.7% |
| 2/26/2025 | 1.6% | 4.6% | 7.4% |
| 10/30/2024 | -22.8% | -26.8% | -22.1% |
| 7/31/2024 | -5.3% | -5.0% | 0.3% |
| 4/23/2024 | 0.6% | -0.5% | -4.2% |
| 2/22/2024 | -2.4% | -5.2% | -2.9% |
| 10/25/2023 | -15.5% | -15.6% | -8.2% |
| 7/27/2023 | 4.4% | 3.7% | 7.2% |
| 5/3/2023 | -16.1% | -17.7% | -12.9% |
| 2/23/2023 | 10.5% | 8.4% | 7.4% |
| 10/27/2022 | -12.1% | -14.2% | -17.6% |
| 7/27/2022 | 2.6% | 8.3% | 1.1% |
| 4/28/2022 | 12.5% | 10.1% | 7.3% |
| 2/23/2022 | 147.9% | 157.3% | 169.6% |
| 10/20/2021 | 6.4% | 13.3% | 11.6% |
| 2/8/2021 | -3.4% | -0.7% | -1.9% |
| 7/20/2020 | 10.1% | -18.3% | -13.0% |
| SUMMARY STATS | |||
| # Positive | 10 | 7 | 9 |
| # Negative | 11 | 14 | 12 |
| Median Positive | 5.4% | 8.4% | 7.4% |
| Median Negative | -8.6% | -9.6% | -10.6% |
| Max Positive | 147.9% | 157.3% | 169.6% |
| Max Negative | -24.3% | -26.8% | -22.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/23/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 10/25/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 07/27/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/23/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 10/25/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 07/27/2022 | 10-Q |
| 03/31/2022 | 04/28/2022 | 10-Q |
| 12/31/2021 | 02/23/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/03/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 03/11/2021 | 10-K |
| 09/30/2020 | 11/03/2020 | 10-Q |
| 06/30/2020 | 08/04/2020 | 10-Q |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 03/05/2020 | 10-K |
| 09/30/2019 | 11/06/2019 | 10-Q |
| 06/30/2019 | 07/31/2019 | 10-Q |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 4/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 5.67 Bil | 5.72 Bil | 5.78 Bil | -3.0% | Lowered | Guidance: 5.90 Bil for 2026 | |
| 2026 EPS | 1.82 | 1.87 | 1.92 | 0 | Affirmed | Guidance: 1.87 for 2026 | |
| 2026 Adjusted EBITDA | 480.00 Mil | 492.50 Mil | 505.00 Mil | 0 | Affirmed | Guidance: 492.50 Mil for 2026 | |
| 2026 Cash provided by operating activities | 320.00 Mil | 320.00 Mil | -5.9% | Lowered | Guidance: 340.00 Mil for 2026 | ||
Prior: Q4 2025 Earnings Reported 2/24/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 5.80 Bil | 5.90 Bil | 6.00 Bil | 4.9% | Higher New | Actual: 5.62 Bil for 2025 | |
| 2026 Adjusted Diluted EPS | 1.82 | 1.87 | 1.92 | 10.0% | Higher New | Actual: 1.7 for 2025 | |
| 2026 Adjusted EBITDA | 480.00 Mil | 492.50 Mil | 505.00 Mil | 4.7% | Higher New | Actual: 470.50 Mil for 2025 | |
| 2026 Cash provided by operating activities | 340.00 Mil | 340.00 Mil | 6.2% | Higher New | Actual: 320.00 Mil for 2025 | ||
Insider Activity
Updated 5/21/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sullivan, Timothy P | Direct | Buy | 5072026 | 20.69 | 24,154 | 499,671 | 1,518,067 | Form | |
| 2 | Sethna, Meenal | Chief Financial Officer | Direct | Buy | 5042026 | 20.16 | 16,225 | 327,075 | 1,982,346 | Form |
| 3 | Rademacher, John Charles | Chief Executive Officer | Direct | Buy | 5042026 | 21.18 | 12,500 | 264,706 | 14,720,886 | Form |
| 4 | Pate, R Carter | Direct | Sell | 3032026 | 32.05 | 30,287 | 970,620 | 372,487 | Form | |
| 5 | Bavaro, Michael | Chief Human Resources Officer | Direct | Sell | 3032026 | 33.00 | 6,000 | 198,000 | 1,097,217 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sullivan, Timothy P | Direct | Buy | 5072026 | 20.69 | 24,154 | 499,671 | 1,518,067 | Form | |
| 2 | Sethna, Meenal | Chief Financial Officer | Direct | Buy | 5042026 | 20.16 | 16,225 | 327,075 | 1,982,346 | Form |
| 3 | Rademacher, John Charles | Chief Executive Officer | Direct | Buy | 5042026 | 21.18 | 12,500 | 264,706 | 14,720,886 | Form |
| 4 | Pate, R Carter | Direct | Sell | 3032026 | 32.05 | 30,287 | 970,620 | 372,487 | Form | |
| 5 | Bavaro, Michael | Chief Human Resources Officer | Direct | Sell | 3032026 | 33.00 | 6,000 | 198,000 | 1,097,217 | Form |
| 6 | Kraemer, Harry M Jansen JR | Direct | Buy | 11042025 | 25.98 | 38,000 | 987,392 | 10,741,526 | Form | |
| 7 | Wright, Norman L | Direct | Buy | 9102025 | 29.31 | 3,411 | 99,976 | 454,333 | Form | |
| 8 | Sullivan, Timothy P | Direct | Buy | 8212025 | 27.51 | 20,000 | 550,200 | 1,354,290 | Form | |
| 9 | Golding, David W | Direct | Buy | 8212025 | 27.62 | 1,000 | 27,625 | 3,219,003 | Form | |
| 10 | Pate, R Carter | Direct | Buy | 8212025 | 27.19 | 750 | 20,391 | 1,139,474 | Form | |
| 11 | Kraemer, Harry M Jansen JR | Direct | Buy | 8212025 | 27.15 | 36,000 | 977,278 | 10,190,562 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.